Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agents

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Hypoxic tumors resist conventional cancer therapies.
• Developing drugs targeting hypoxic cancer cells is crucial for effective treatment.
• Quinoxaline 1,4-dioxides (QdNOs) are a promising class of compounds with potential anticancer activity.

Purpose of the Study:

• To evaluate the hypoxia-selective toxicity of various QdNO derivatives.
• To determine the effect of these compounds on hypoxia-inducible factor 1-alpha (HIF-1alpha) expression.
• To identify structural features contributing to selective cytotoxicity in hypoxic conditions.

Main Methods:

• Cytotoxicity assays on T-84 colon cancer cells under hypoxic and normoxic conditions.
• Assessment of HIF-1alpha transcript and protein levels via RT-PCR and Western blotting.
• Structure-activity relationship analysis of four substituted QdNOs.

Main Results:

• QdNOs exhibited 50- to 100-fold greater cytotoxicity in hypoxic versus normoxic conditions.
• The dichloro derivative (DCQ) showed the highest potency (1 microM) and hypoxia cytotoxicity ratio (HCR) of 100.
• DCQ significantly reduced HIF-1alpha levels, unlike less cytotoxic analogues.
• Chlorination at the C-6, C-7 positions appeared critical for DCQ's selective hypoxic toxicity.

Conclusions:

• Substituted quinoxaline 1,4-dioxides demonstrate significant hypoxia-selective cytotoxicity.
• The dichloro derivative (DCQ) is a potent candidate for targeting hypoxic tumors.
• Structure-activity relationships, particularly chlorination, influence the efficacy and selectivity of QdNOs against hypoxic cancer cells.